PMID- 26582698
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20181202
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
VI  - 194
IP  - 6
DP  - 2015 Dec
TI  - Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk 
      of Malignant Melanoma.
PG  - 1710-1
LID - 10.1016/j.juro.2015.09.030 [doi]
LID - S0022-5347(15)04760-6 [pii]
FAU - Penson, David F
AU  - Penson DF
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20151023
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Phosphodiesterase 5 Inhibitors)
SB  - AIM
SB  - IM
CON - JAMA. 2015 Jun 23-30;313(24):2449-55. PMID: 26103029
CIN - J Urol. 2016 Apr;195(4 Pt 1):1172-3. PMID: 26783933
MH  - Animals
MH  - Erectile Dysfunction/*drug therapy
MH  - Humans
MH  - Male
MH  - Melanoma/*chemically induced
MH  - Phosphodiesterase 5 Inhibitors/*adverse effects
MH  - Skin Neoplasms/*chemically induced
EDAT- 2015/11/20 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/11/20 06:00
PHST- 2015/09/04 00:00 [accepted]
PHST- 2015/11/20 06:00 [entrez]
PHST- 2015/11/20 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - S0022-5347(15)04760-6 [pii]
AID - 10.1016/j.juro.2015.09.030 [doi]
PST - ppublish
SO  - J Urol. 2015 Dec;194(6):1710-1. doi: 10.1016/j.juro.2015.09.030. Epub 2015 Oct
      23.